They reported a novel pharmacodynamic effect of navitoclax on peripheral thrombocytopenia and T-cell lymphopenia in treating lymphoid tumors owing to high affinity inhibitions of BCL-2 and BCL-XL proteins (Wilson et al., 2010). The gene discussed is BCL2L1; the disease is lymphoid neoplasm.